Diabetes: Anti-PCSK9 antibodies — beneficial or inducers of diabetes?

Diabetes: Anti-PCSK9 antibodies — beneficial or inducers of diabetes?, Published online: 09 November 2017; doi:10.1038/nrendo.2017.145

NatureArticleSnippet(type=standfirst, markup=

A recent study has shown that evolocumab, an injectable monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), robustly reduces levels of LDL cholesterol and decreases the risk of cardiovascular disease in patients with and without diabetes mellitus. When given on top of statins, evolocumab does not induce diabetes mellitus.

, isJats=true)

中文翻译：

---

糖尿病：抗PCSK9抗体-糖尿病的有益还是诱导剂？

糖尿病：抗PCSK9抗体-糖尿病的有益还是诱导剂？

糖尿病：抗PCSK9抗体-糖尿病的有益还是诱导剂？，在线发布：2017年11月9日；doi：10.1038 / nrendo.2017.145

NatureArticleSnippet（type = standfirst，markup =

最近的一项研究表明，evolocumab是一种针对原蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（PCSK9）的可注射单克隆抗体，可有效降低LDL胆固醇水平，并降低患有或不患有糖尿病的患者的心血管疾病风险。当服用他汀类药物时，evolocumab不会诱发糖尿病。

，isJats = true）